Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acquiree, addressing, al, analyst, arisen, attack, bacteria, borrowing, captioned, CAR, checkpoint, Chimera, commensurate, Concurrent, concurrently, conserved, contemplated, cooperating, customary, CVR, Delaware, disadvantage, discourage, disposition, disseminate, District, enjoining, entry, evolution, exacerbated, facilitating, factual, fixed, Florida, forma, FxTM, gave, headcount, IFx, immune, immunity, immunosuppressive, impression, inclined, inducing, injunction, innate, inquiry, intangible, intratumoral, iv, knowingly, legacy, lesser, line, majeure, maximum, MergeCo, merit, messenger, microenvironment, misleading, modulate, mutual, myeloid, Northern, notwithstanding, open, overcome, pendency, plasmid, political, prepaid, pro, promulgated, purported, purportedly, putative, quorum, recapitalization, redeem, refunded, relief, renegotiate, rescinding, rescissory, resistance, RNA, running, science, single, soliciting, Statement, subsidiary, suppressor, surviving, takeover, tangible, tenor, terrorism, thereunder, top, trick, TuHURA, tumor, unsolicited, untrue, usage, voting, waived, waiver, war, wholly
Removed:
acid, biological, built, characterize, distinct, encoding, explore, exploring, function, important, mitochondrially, native, nucleic, optimizing, partnership, recently, systemic
Financial report summary
?Competition
Pfizer • AMGEN • Cognex • Gilead Sciences • FibroGen • Durect • Exelon • Madrigal Pharmaceuticals • Intercept Pharmaceuticals • Edesa BiotechManagement Discussion
- Research and development expenses were $0.2 million in the three months ended June 30, 2023 compared to $1.2 million in the prior year period, a decrease of $1.0 million, or 85%. The lower research and development expenses was primarily due to a decrease of $0.6 million associated with our research programs related to the suspension of our activities, a $0.2 million decrease in compensation costs due to lower headcount in the current year period and a $0.1 million decrease in rent expense as we reduced the amount of office space leased.
- General and administrative expenses were $4.3 million in the three months ended June 30, 2023 compared to $1.6 million in the prior year period, an increase of $2.7 million, or 173%. The increase in general and administrative expenses was due to a $1.7 million increase in professional fees primarily due to costs related to the Merger and a $1.2 million compensation charge incurred in the current year period related to the retention of our key executives. These increases were partially offset by lower compensation costs and directors fees of $0.2 million primarily due to the decrease in stock-based compensation of $0.1 million.